Follow us

NH TherAguix NEWS

NH TherAguix announces the launch of its IPO on the Euronext Growth market in Paris

Grenoble (France), 28 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the launch of its initial public offering with a view to listing its shares on the Euronext Growth market (ISIN code: FR0013105954 – ticket: ALNHT).

View Press Release

 

Categories

 

Archives